Do Genetic Polymorphisms Affect Fetal Hemoglobin (HbF) Levels in Patients With Sickle Cell Anemia Treated With Hydroxyurea? A Systematic Review and Pathway Analysis

Hydroxyurea has long been used for the treatment of sickle cell anemia (SCA), and its clinical effectiveness is related to the induction of fetal hemoglobin (HbF), a major modifier of SCA phenotypes. However, there is substantial variability in response to hydroxyurea among patients with SCA. While...

Descripción completa

Detalles Bibliográficos
Autores principales: Sales, Rahyssa Rodrigues, Nogueira, Bárbara Lisboa, Tosatti, Jéssica Abdo Gonçalves, Gomes, Karina Braga, Luizon, Marcelo Rizzatti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814522/
https://www.ncbi.nlm.nih.gov/pubmed/35126118
http://dx.doi.org/10.3389/fphar.2021.779497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814522/
https://www.ncbi.nlm.nih.gov/pubmed/35126118
http://dx.doi.org/10.3389/fphar.2021.779497

Ejemplares similares